{"id":61524,"date":"2024-03-29T14:52:10","date_gmt":"2024-03-29T14:52:10","guid":{"rendered":"https:\/\/www.africa-press.net\/tchad\/politique\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent"},"modified":"2024-03-29T15:36:13","modified_gmt":"2024-03-29T15:36:13","slug":"limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent","status":"publish","type":"post","link":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent","title":{"rendered":"L’immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent"},"content":{"rendered":"

Africa-Press – Tchad. <\/strong><\/span>Impressionnants me\u0302me si encore tre\u0300s pre\u0301liminaires et transitoires. Les premiers re\u0301sultats d\u2019une nouvelle immunothe\u0301rapie teste\u0301e face au glioblastome, un type de tumeur ce\u0301re\u0301brale (3500 morts par an en France), viennent d\u2019e\u0302tre publie\u0301s dans une e\u0301tude parue dans la revue New England Journal of Medicine.<\/p>\n

Des cellules modifie\u0301es en laboratoire<\/b><\/p>\n

Mene\u0301 pour la premie\u0300re fois aupre\u0300s d’uniquement trois patients, cet essai, \u00ab\u00a0Incipient\u00a0\u00bb, de phase 1, a e\u0301te\u0301 conduit par l\u2019e\u0301quipe ame\u0301ricaine du Mass General Brigham (MGB) Cancer Center (Boston). Il repose sur la technique dite des CAR-T (Chimeric Antigen Receptor-T) cells (voir SetA n\u00b0824) et a mis en e\u0301vidence une diminution rapide et spectaculaire de la taille des tumeurs. Proble\u0300me: cette re\u0301duction e\u0301tait uniquement transitoire.<\/p>\n

Pour rappel, cette technique fonctionne en utilisant les propres cellules immunitaires des malades, les lymphocytes T. Une approche personnalise\u0301e (et tre\u0300s cou\u0302teuse) consistant, une fois la prise de sang re\u0301alise\u0301e, a\u0300 modifier en laboratoire ces cellules pour produire a\u0300 leur surface des prote\u0301ines appele\u0301es re\u0301cepteurs d’antige\u0300nes chime\u0301riques (ici EGfr). La pre\u0301paration cellulaire ainsi obtenue est ensuite re\u0301injecte\u0301e dans le corps du patient afin que les cellules s\u2019attaquent directement a\u0300 sa tumeur pour mieux la de\u0301truire.<\/p>\n

Une combinaison de deux approches<\/b><\/p>\n

Cette approche est teste\u0301e depuis de\u0301ja\u0300 quelques anne\u0301es, au de\u0301but dans les leuce\u0301mies puis aussi dans certaines tumeurs solides comme celles se de\u0301veloppant au niveau ce\u0301re\u0301bral. Mais celles-ci sont souvent tre\u0300s he\u0301te\u0301roge\u0300nes sur le plan cellulaire. Et quelques cellules cance\u0301reuses continuent dans ce cas d\u2019e\u0301chapper a\u0300 la de\u0301tection du syste\u0300me immunitaire, me\u0302me apre\u0300s une the\u0301rapie par CAR-T.<\/p>\n

Ici, l\u2019e\u0301quipe ame\u0301ricaine a combine\u0301 deux approches, le CAR-T avec des anticorps bispe\u0301cifiques, connus sous le nom de mole\u0301cules d’anticorps engageant les lymphocytes T (TEAM). L’objectif: cibler justement des populations cellulaires mixtes au sein me\u0302me des tumeurs et imposant que les \u00ab\u00a0cellules me\u0301dicaments\u00a0\u00bb obtenues soient re\u0301injecte\u0301es en intrace\u0301re\u0301bral par l\u2019interme\u0301diaire d\u2019un re\u0301servoir implante\u0301 au niveau ce\u0301re\u0301bral lors d\u2019une intervention chirurgicale.<\/p>\n

Une tumeur a quasiment disparu<\/b><\/p>\n

Les trois patients inclus dans \u00ab\u00a0Incipient\u00a0\u00bb, deux hommes et une femme, e\u0301taient tous en phase de re\u0301cidive et avaient rec\u0327u au pre\u0301alable une radiothe\u0301rapie standard associe\u0301e a\u0300 une chimiothe\u0301rapie standard (temozolomide). Dans cette e\u0301tude, apre\u0300s une seule infusion intrace\u0301re\u0301brale, les tumeurs ont spectaculairement diminue\u0301 de volume, l\u2019une d\u2019entre elle ayant quasiment disparu selon les de\u0301tails diffuse\u0301s par l\u2019ho\u0302pital de Boston de\u0301crivant pre\u0301cise\u0301ment les cas de chacun des trois patients.<\/p>\n

Un homme de 74 ans a vu sa tumeur re\u0301gresser rapidement, quand chez un autre de 72 ans, deux jours apre\u0300s avoir rec\u0327u des cellules CAR-TEAM, l\u2019IRM a montre\u0301 une diminution de la taille de la tumeur de 18,5 %. Au deuxie\u0300me mois, la tumeur avait me\u0302me diminue\u0301 de 60,7% et la re\u0301ponse s’est maintenue pendant plus de six mois. Enfin, pour la femme a\u0302ge\u0301e de 57 ans, cinq jours apre\u0300s le traitement, la re\u0301gression tumorale e\u0301tait presque comple\u0300te.<\/p>\n

Malheureusement, dans ces trois cas, ces effets impressionnants se sont ave\u0301re\u0301s n’e\u0302tre que transitoires puisque dans les semaines et mois qui ont suivi, tous ont fini par faire une rechute. Reste que cette e\u0301tude est la premie\u0300re a\u0300 apporter la preuve de concept de sa faisabilite\u0301. Les chercheurs vont maintenant devoir comprendre pourquoi l\u2019effet s\u2019est atte\u0301nue\u0301 aussi vite et quelles sont les raisons de la disparition des cellules CAR-T ou de leur perte d\u2019efficacite\u0301.<\/p>\n

Pour plus d’informations et d’analyses sur la Tchad<\/a>, suivez Africa-Press<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Africa-Press – Tchad. Impressionnants me\u0302me si encore tre\u0300s pre\u0301liminaires et transitoires. Les premiers re\u0301sultats d\u2019une nouvelle immunothe\u0301rapie teste\u0301e face au glioblastome, un type de tumeur ce\u0301re\u0301brale (3500 morts par an en France), viennent d\u2019e\u0302tre publie\u0301s dans une e\u0301tude parue dans la revue New England Journal of Medicine. Des cellules modifie\u0301es en laboratoire Mene\u0301 pour la […]<\/p>\n","protected":false},"author":82,"featured_media":61523,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22,10],"tags":[37,292,29],"class_list":["post-61524","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-divers","category-toutes-les-actualites","tag-africa-press","tag-africa-press-tchad","tag-tchad"],"yoast_head":"\nL'immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent - tchad<\/title>\n<meta name=\"description\" content=\"Impressionnants me\u0302me si encore tre\u0300s pre\u0301liminaires et transitoires. Les premiers re\u0301sultats d\u2019une nouvelle immunothe\u0301r ...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L'immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent\" \/>\n<meta property=\"og:description\" content=\"Impressionnants me\u0302me si encore tre\u0300s pre\u0301liminaires et transitoires. Les premiers re\u0301sultats d\u2019une nouvelle immunothe\u0301r ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent\" \/>\n<meta property=\"og:site_name\" content=\"tchad\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-29T14:52:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-29T15:36:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/static.africa-press.net\/tchad\/sites\/41\/2024\/03\/sm_1711712588.7641.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"cfeditorfr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"cfeditorfr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent\"},\"author\":{\"name\":\"cfeditorfr\",\"@id\":\"https:\/\/www.africa-press.net\/tchad\/#\/schema\/person\/2b1cf3cd81a31e3cd26889ca66d677f1\"},\"headline\":\"L’immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent\",\"datePublished\":\"2024-03-29T14:52:10+00:00\",\"dateModified\":\"2024-03-29T15:36:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent\"},\"wordCount\":684,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#primaryimage\"},\"thumbnailUrl\":\"https:\/\/static.africa-press.net\/tchad\/sites\/41\/2024\/03\/sm_1711712588.7641.jpg\",\"keywords\":[\"Africa Press\",\"Africa Press-Tchad\",\"Tchad\"],\"articleSection\":[\"Divers\",\"Toutes les actualit\u00e9s\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent\",\"url\":\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent\",\"name\":\"L'immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent - tchad\",\"isPartOf\":{\"@id\":\"https:\/\/www.africa-press.net\/tchad\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#primaryimage\"},\"thumbnailUrl\":\"https:\/\/static.africa-press.net\/tchad\/sites\/41\/2024\/03\/sm_1711712588.7641.jpg\",\"datePublished\":\"2024-03-29T14:52:10+00:00\",\"dateModified\":\"2024-03-29T15:36:13+00:00\",\"author\":{\"@id\":\"https:\/\/www.africa-press.net\/tchad\/#\/schema\/person\/2b1cf3cd81a31e3cd26889ca66d677f1\"},\"description\":\"Impressionnants me\u0302me si encore tre\u0300s pre\u0301liminaires et transitoires. Les premiers re\u0301sultats d\u2019une nouvelle immunothe\u0301r ...\",\"breadcrumb\":{\"@id\":\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#primaryimage\",\"url\":\"https:\/\/static.africa-press.net\/tchad\/sites\/41\/2024\/03\/sm_1711712588.7641.jpg\",\"contentUrl\":\"https:\/\/static.africa-press.net\/tchad\/sites\/41\/2024\/03\/sm_1711712588.7641.jpg\",\"width\":1200,\"height\":900,\"caption\":\"L'immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.africa-press.net\/tchad\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L’immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.africa-press.net\/tchad\/#website\",\"url\":\"https:\/\/www.africa-press.net\/tchad\/\",\"name\":\"tchad\",\"description\":\"Just another Africa News Agency Sites site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.africa-press.net\/tchad\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.africa-press.net\/tchad\/#\/schema\/person\/2b1cf3cd81a31e3cd26889ca66d677f1\",\"name\":\"cfeditorfr\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"L'immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent - tchad","description":"Impressionnants me\u0302me si encore tre\u0300s pre\u0301liminaires et transitoires. Les premiers re\u0301sultats d\u2019une nouvelle immunothe\u0301r ...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent","og_locale":"fr_FR","og_type":"article","og_title":"L'immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent","og_description":"Impressionnants me\u0302me si encore tre\u0300s pre\u0301liminaires et transitoires. Les premiers re\u0301sultats d\u2019une nouvelle immunothe\u0301r ...","og_url":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent","og_site_name":"tchad","article_published_time":"2024-03-29T14:52:10+00:00","article_modified_time":"2024-03-29T15:36:13+00:00","og_image":[{"width":1200,"height":900,"url":"https:\/\/static.africa-press.net\/tchad\/sites\/41\/2024\/03\/sm_1711712588.7641.jpg","type":"image\/jpeg"}],"author":"cfeditorfr","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"cfeditorfr","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#article","isPartOf":{"@id":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent"},"author":{"name":"cfeditorfr","@id":"https:\/\/www.africa-press.net\/tchad\/#\/schema\/person\/2b1cf3cd81a31e3cd26889ca66d677f1"},"headline":"L’immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent","datePublished":"2024-03-29T14:52:10+00:00","dateModified":"2024-03-29T15:36:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent"},"wordCount":684,"commentCount":0,"image":{"@id":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#primaryimage"},"thumbnailUrl":"https:\/\/static.africa-press.net\/tchad\/sites\/41\/2024\/03\/sm_1711712588.7641.jpg","keywords":["Africa Press","Africa Press-Tchad","Tchad"],"articleSection":["Divers","Toutes les actualit\u00e9s"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent","url":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent","name":"L'immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent - tchad","isPartOf":{"@id":"https:\/\/www.africa-press.net\/tchad\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#primaryimage"},"image":{"@id":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#primaryimage"},"thumbnailUrl":"https:\/\/static.africa-press.net\/tchad\/sites\/41\/2024\/03\/sm_1711712588.7641.jpg","datePublished":"2024-03-29T14:52:10+00:00","dateModified":"2024-03-29T15:36:13+00:00","author":{"@id":"https:\/\/www.africa-press.net\/tchad\/#\/schema\/person\/2b1cf3cd81a31e3cd26889ca66d677f1"},"description":"Impressionnants me\u0302me si encore tre\u0300s pre\u0301liminaires et transitoires. Les premiers re\u0301sultats d\u2019une nouvelle immunothe\u0301r ...","breadcrumb":{"@id":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#primaryimage","url":"https:\/\/static.africa-press.net\/tchad\/sites\/41\/2024\/03\/sm_1711712588.7641.jpg","contentUrl":"https:\/\/static.africa-press.net\/tchad\/sites\/41\/2024\/03\/sm_1711712588.7641.jpg","width":1200,"height":900,"caption":"L'immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent"},{"@type":"BreadcrumbList","@id":"https:\/\/www.africa-press.net\/tchad\/toutes-les-actualites\/limmunotherapie-face-au-glioblastome-le-cancer-du-cerveau-le-plus-frequent#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.africa-press.net\/tchad\/"},{"@type":"ListItem","position":2,"name":"L’immunoth\u00e9rapie face au glioblastome, le cancer du cerveau le plus fr\u00e9quent"}]},{"@type":"WebSite","@id":"https:\/\/www.africa-press.net\/tchad\/#website","url":"https:\/\/www.africa-press.net\/tchad\/","name":"tchad","description":"Just another Africa News Agency Sites site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.africa-press.net\/tchad\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.africa-press.net\/tchad\/#\/schema\/person\/2b1cf3cd81a31e3cd26889ca66d677f1","name":"cfeditorfr"}]}},"_links":{"self":[{"href":"https:\/\/www.africa-press.net\/tchad\/wp-json\/wp\/v2\/posts\/61524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.africa-press.net\/tchad\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.africa-press.net\/tchad\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.africa-press.net\/tchad\/wp-json\/wp\/v2\/users\/82"}],"replies":[{"embeddable":true,"href":"https:\/\/www.africa-press.net\/tchad\/wp-json\/wp\/v2\/comments?post=61524"}],"version-history":[{"count":0,"href":"https:\/\/www.africa-press.net\/tchad\/wp-json\/wp\/v2\/posts\/61524\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.africa-press.net\/tchad\/wp-json\/wp\/v2\/media\/61523"}],"wp:attachment":[{"href":"https:\/\/www.africa-press.net\/tchad\/wp-json\/wp\/v2\/media?parent=61524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.africa-press.net\/tchad\/wp-json\/wp\/v2\/categories?post=61524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.africa-press.net\/tchad\/wp-json\/wp\/v2\/tags?post=61524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}